Join the Imfinzi group to help and get support from people like you.
Imfinzi News
An Artificial Sweetener May Hamper Immunotherapy Cancer Treatment
MONDAY, Aug. 4, 2025 — Findings from a study in mice suggest that using a common artificial sweetener, sucralose, could hamper certain immunotherapy treatments in cancer patients. However, for folks ...
Autoantibodies Influence Cancer Response To Immunotherapy, Study Says
MONDAY, July 28, 2025 — Cutting-edge immunotherapy drugs are incredibly effective against some cancers but barely put a dent in others – and researchers might now know why. Patients’ own autoa...
Immune Checkpoint Inhibitor Affordability Tied to Widening Survival Disparity
FRIDAY, July 11, 2025 – The introduction of immune checkpoint inhibitors (ICIs) was associated with a widening survival disparity between those with private insurance and those without health...
Insured? You're More Likely To Survive Cancer Through Immunotherapy Treatment
WEDNESDAY, July 9, 2025 — Powerful new immunotherapies are offering fresh hope for patients with many different types of cancer. Unfortunately, that hope doesn’t extend to people without health ins...
Clash Of Drugs Impedes Lung Cancer Treatment, Lowers Survival
TUESDAY, July 7, 2025 — Two drugs used in lung cancer treatment appear to be tripping over each other, reducing patients’ chances for a cure, a new study says. Corticosteroids are commonly prescribed ...
Immunotherapy Effective Against Stomach Cancer
FRIDAY, June 6, 2025 — Immunotherapy combined with chemo can give people a fighting chance against stomach and esophageal cancers, a new clinical trial says. People treated with durvalumab and c...
ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer
THURSDAY, June 5, 2025 – For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) yields better...
FDA Approves Imfinzi (durvalumab) for Muscle Invasive Bladder Cancer
On March 28, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant...
Monthly News Roundup - March 2025
FDA Approves Tremfya for Adults Patients with Active Crohn’s Disease In March, Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approval of Tremfya (guselkumab) for the t...
Radiotherapy With Adjuvant Durvalumab No Benefit for Head, Neck Cancer
MONDAY, Dec. 9, 2024 – For patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) with a contraindication for cisplatin, radiotherapy with adjuvant durvalumab does not...
Imfinzi Approved in the US as First and Only Immunotherapy Regimen for Patients with Limited-Stage Small Cell Lung Cancer
5 December 2024 – AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not p...
There's a Best Option for Patients With Head-and-Neck Cancer Who Can't Take Cisplatin
TUESDAY, Nov. 26, 2024 – Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but nearly a third of patients can't tolerate its side effects and quit the drug. A new trial...
Adjuvant Durvalumab Extends Survival in Small Cell Lung Cancer
THURSDAY, Sept. 19, 2024 – For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer overall and progression-free survival, according to...
Monthly News Roundup - August 2024
FDA Clears Pfizer and Moderna 2024-2025 COVID-19 mRNA Vaccines On August 22, the FDA approved the latest COVID-19 mRNA monovalent vaccines from Moderna (Spikevax) and Pfizer / BioNTech (Comirnaty) ...
Imfinzi Approved in the US for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery
16 August 2024 – AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the US for the treatment of adult patients with resectable early-stage (IIA-IIIB) non-small c...
Further information
Related condition support groups
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma, Endometrial Cancer